Several clinical trials, encompassing Phase 2 studies and unassigned protocols, are evaluating interventions for human papillomavirus (HPV) infection and cervical intraepithelial neoplasia grade 2 (CIN2), with all currently marked as not yet recruiting. Key research initiatives examine diagnostic performance in CIN2 management, pBI-11 administration for HPV16/18-positive conditions, and vaginal sampling methods for high-risk HPV detection. Sponsored by leading European, American, and international institutions—such as the European Institute of Oncology, Johns Hopkins, and FIND Switzerland alongside African research partners—these studies aim to advance early detection and targeted management of HPV-associated cervical dysplasias.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06403618 | Not yet recruiting | Cervical Intraepithelial Neoplasia Grade 2 |
European Institute of Oncology |
2024-05-15 | -- |
| NCT06210854 | Not yet recruiting | HPV Infection |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2024-05 | Phase 2 |
| NCT06213051 | Not yet recruiting | Human Papillomavirus Infection |
Foundation for Innovative New Diagnostics Switzerland|Kenya Medical Research Institute|Frere Hospital East London South Africa |
2024-04-01 | -- |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).